Back to search
FDAFDA · Food and drugs·Recall number D-0502-2024

Xelpros (latanoprost ophthalmic emulsion) 0.005%, 125mcg/2.5mL, 2.5 mL bottle, Rx only, Manufactured by: Sun Pharmaceutical Ind. Ltd., India., NDC 47335-317-90

Published May 29, 2024 · Recall initiated: April 22, 2024

Summary

FDA records drug Class III recall D-0502-2024, published May 29, 2024 and initiated April 22, 2024. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Ongoing; Reported quantity: 35,069 bottles; Lot: Lot #: HAD3383A, Exp 8/31/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Release Testing: Out of specification for particulate matter test.

What to do

Voluntary: Firm initiated · Letter

Get an email if XELPROS has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
XELPROS
Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Distributor
TX, PA
Lot
Lot #: HAD3383A, Exp 8/31/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Xelpros (latanoprost ophthalmic emulsion) 0.005%, 125mcg/2.5mL, 2.5 mL bottle, Rx only, Manufactured by: Sun Pharmaceutical Ind. Ltd., India., NDC 47335-317-90 recalled?

Yes. FDA published recall D-0502-2024 on May 29, 2024. Reported hazard: Failed Release Testing: Out of specification for particulate matter test.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: XELPROS.